Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure

F.E. Karet, Claire Dickerson, J. Brown, M.J. Brown

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.
Original languageEnglish
Pages (from-to)1263-1265
JournalLancet
Volume344
Issue number8932
DOIs
Publication statusPublished - 1994

Fingerprint

Dive into the research topics of 'Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure'. Together they form a unique fingerprint.

Cite this